News
Daewoong Pharmaceutical and SCAI Therapeutics begin joint development of transdermal absorption formulation treatment.
Author
SCAI Therapeutics
Date
2022-06-29 22:51
Views
746
Daewoong Pharmaceutical (CEO Seung-ho Jeon and Chang-jae Lee) signed a joint R&D contract with SCAI Therapeutics (CEO Chul Hwan Kim), a drug delivery platform bioventure company, on the 28th as part of the ‘2030 Global Drug No.1 Vision’.
Through this agreement, the two companies plan to apply SCAI Therapeutics' own technology to develop transdermal absorption formulations with substances with increased solubility and body absorption as their main ingredients, and to jointly research and develop treatments for various chronic skin diseases as indications. SCAI Therapeutics supplies a drug substance with improved bioavailability, and Daewoong Pharmaceutical develops the drug substance into a drug product and is in charge of preclinical and clinical trials.
SCAI Therapeutics is a bio-venture company established in 2019 and has ‘MOASIS™, a drug delivery technology platform that can improve the bioavailability of poorly soluble drugs. The MOASIS™ is a technology that improves bioavailability by maximizing drug solubility and absorption in the body, and through this, it is possible to improve existing products, change administration routes, and expand new indications.
According to Daewoong Pharmaceutical, the transdermal drug that the two companies plan to jointly develop is a drug that exhibits medicinal effects when applied or attached to the skin. Therefore, unlike general oral formulations, it does not pass through the gastrointestinal tract, so it can avoid side effects in the digestive system or drug inactivation due to the first-pass effect in the liver.
Over time, the drug has the property of crystallizing, which may affect the efficacy of the drug, but SCAI Therapeutics explained that, with SCAI Therapeutics' MOASIS™ platform technology, it is expected that it will be possible to commercialize drugs that have been difficult to develop due to their poor absorption and solubility.
Seung-ho Jeon, CEO of Daewoong Pharmaceutical, said, “We are looking forward to securing a new percutaneous absorption formulation pipeline by combining SCAI Therapeutics’ unique drug delivery platform and Daewoong Pharmaceutical’s innovative research technology. Through this agreement, we will establish a long-term cooperative relationship between SCAI Therapeutics and Daewoong Pharmaceutical.”
Chul Hwan Kim, CEO of SCAI Therapeutics, said, "We will make efforts to show results in the development of transdermal absorption formulations through research cooperation with Daewoong Pharmaceutical, which has excellent new drug development capabilities."
Through this agreement, the two companies plan to apply SCAI Therapeutics' own technology to develop transdermal absorption formulations with substances with increased solubility and body absorption as their main ingredients, and to jointly research and develop treatments for various chronic skin diseases as indications. SCAI Therapeutics supplies a drug substance with improved bioavailability, and Daewoong Pharmaceutical develops the drug substance into a drug product and is in charge of preclinical and clinical trials.
SCAI Therapeutics is a bio-venture company established in 2019 and has ‘MOASIS™, a drug delivery technology platform that can improve the bioavailability of poorly soluble drugs. The MOASIS™ is a technology that improves bioavailability by maximizing drug solubility and absorption in the body, and through this, it is possible to improve existing products, change administration routes, and expand new indications.
According to Daewoong Pharmaceutical, the transdermal drug that the two companies plan to jointly develop is a drug that exhibits medicinal effects when applied or attached to the skin. Therefore, unlike general oral formulations, it does not pass through the gastrointestinal tract, so it can avoid side effects in the digestive system or drug inactivation due to the first-pass effect in the liver.
Over time, the drug has the property of crystallizing, which may affect the efficacy of the drug, but SCAI Therapeutics explained that, with SCAI Therapeutics' MOASIS™ platform technology, it is expected that it will be possible to commercialize drugs that have been difficult to develop due to their poor absorption and solubility.
Seung-ho Jeon, CEO of Daewoong Pharmaceutical, said, “We are looking forward to securing a new percutaneous absorption formulation pipeline by combining SCAI Therapeutics’ unique drug delivery platform and Daewoong Pharmaceutical’s innovative research technology. Through this agreement, we will establish a long-term cooperative relationship between SCAI Therapeutics and Daewoong Pharmaceutical.”
Chul Hwan Kim, CEO of SCAI Therapeutics, said, "We will make efforts to show results in the development of transdermal absorption formulations through research cooperation with Daewoong Pharmaceutical, which has excellent new drug development capabilities."